Atossa plunges following FDA request for information on ForeCYTE

|About: Atossa Genetics, Inc. (ATOS)|By:, SA News Editor

Atossa Genetics (ATOS) plummets 20% after the FDA requests more information about the company's 510(k) application for its ForeCYTE Breast Aspirator health test device.

Atossa intends to request an extension to the 30 day limit that the FDA sets for providing a response; if granted, Atossa could have up 180 days to answer.

Atossa says it doesn't view the FDA's request "as unusual or unexpected." (PR)